June 28, 2017 3:49 AM ET


Company Overview of Vedantra Pharmaceuticals, Inc.

Company Overview

Vedantra Pharmaceuticals, Inc. develops nanotechnology based vaccines for infectious diseases and cancers. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.

Building 1400 West

One Kendall Square

Suite 14303

Cambridge, MA 02139

United States

Founded in 2011





Key Executives for Vedantra Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Executive Chairman
Age: 61
Compensation as of Fiscal Year 2016.

Vedantra Pharmaceuticals, Inc. Key Developments

Vedantra Pharmaceuticals Announces Joint Research Collaboration with Neon Therapeutics to Develop Cancer Vaccines

Vedantra Pharmaceuticals, Inc. announced a joint collaboration to explore cancer vaccine research with Neon Therapeutics. The two companies will contribute their respective expertise non-exclusively to explore the potential benefits of combining Vedantra’s cutting edge albumin-binding, lymph node targeting amphiphile technology with Neon’s innovative capabilities in neoantigen vaccine research. The objective of the joint research collaboration is to continue development of therapeutic vaccines that raise immune responses against neoantigens that allow the body to naturally expand immune cells capable of destroying infected or cancerous cells without harming normal tissues.

Julian Adams Joins Vedantra Pharmaceuticals, Inc. as Executive Chairman

Vedantra Pharmaceuticals, Inc. announced the appointment of Julian Adams, Ph.D. as Executive Chairman. Dr. Adams, who recently stepped down as President of Research and Development at Infinity Pharmaceuticals, will oversee strategic and operational responsibilities, fund raising and drive R&D program development for the company. Dr. Adams has more than 30 years of experience in drug discovery and development with a strong focus on oncology. Dr. Adams previously served as President of Research and Development at Infinity Pharmaceuticals where he was responsible for the full spectrum of drug discovery, preclinical and clinical development, and regulatory affairs activities. Prior to joining Infinity, Dr. Adams was the Senior Vice President of Drug Discovery and Development at Millennium Pharmaceuticals, where he headed multiple global drug discovery programs, including the successful Velcade® (bortezomib) program for multiple myeloma. Dr. Adams also held senior positions in research and development at LeukoSite (acquired by Millennium) and at ProScript, as well as in Boehringer Ingelheim, where he was credited with the discovery of Viramune® (nevirapine) for HIV. Dr. Adams was recently named Chairman of the Board at Gamida Cell.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Vedantra Pharmaceuticals, Inc., please visit vedantra.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.